CLINICAL ROLE -
COVID-19 Pandemic Brought Changes, Requiring Significant Adjustments in Health Systems
Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.
Read More
Role of the Pharmacist in Institutional Readiness, Patient Readiness for Bispecifics
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.
Watch
Insights, Future Considerations in FLT3 Inhibitors Following Allo-HCT in Patients With AML
In this NCCN session, James M. Foran, MD, described the different FLT3 inhibitors that are available for FLT3-mutated AML, as well as considerations for the future.
New, Emerging Treatment Options for Patients With Multiple Myeloma
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.
Lawyer Shares Outlook on DIR Fees and Reimbursement for Community Oncology Pharmacies in 2024
Jonathan Levitt, Esq, discusses legislation and legal action taken to rein in pharmacy benefit managers’ DIR fees.
Assessing Cost vs Margin of Care for Cancer Drugs in Pharmacy Practices
Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.
With the Rapid Expansion of NSCLC Therapy Options, Pharmacists Take an Advanced Role on the Care Team
Whitney Lewis, PharmD, BCOP, discusses how the treatment armamentarium for NSCLC has expanded in recent years and the associated cause for this acceleration.
Bispecifics in Multiple Myeloma: Insights on Operational Readiness and Patient Care
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.
The Role of Oncology Pharmacists Is Evolving in Early-Stage Breast Cancer Treatment Optimization
Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.
Approaching Ethical Dilemmas in Oncology Pharmacy
Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.
Psychedelic Medicine Could Fill Care Gap in Psychiatric Care
However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.
Digital Therapeutics Might Address Gaps in Care for Mental Health Patients
Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.
Understanding Social Determinants of Health and Their Impact on Mental Illness Treatment
Pharmacists can address social determinants to improve patient well-being and treatment.
Managing Insomnia in Special Populations and Treatment-Resistant Cases
Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.
Anticholinergic Medications in Older Adults and Strategies for Safe Deprescribing
Linking strong anticholinergic medications to increased risk of dementia in older adults
Pharmacists Improve Quality of Depression Care at Patient, Community Levels
Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.
Newest Indication for Bempedoic Acid Expands Patient Population
In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.
Expert: New Schizophrenia Treatments Targeting Muscarinic Receptors
Potential for integration into care and future advancements for gaps in current schizophrenia treatments
More Research Needed for Treatment of Clozapine-Resistant Schizophrenia
Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.
Patient Preferences Play Essential Part in Contraceptive Care
Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.
Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure
The finding did not reach statistical significance in the primary composite endpoint.
Novel Approaches to Treating the Full Spectrum of Schizophrenia Symptoms, Modulating Dopamine and Glutamate Neurotransmission
New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.
Pharmacists Facilitate Harm Reduction for Patients With Anxiety Using Cannabis
Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.
Expert: The Evolving Landscape of Pharmacologic Research and Clinical Management of Symptoms in Borderline Personality Disorder
Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder
Exploring Treatment Options for Patients with Treatment-Resistant Schizophrenia
Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia
New Data Shows Positive Results for Sotagliflozin for Patients With Chronic Kidney Disease, Diabetes
The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.
Novel Drugs Targeting Different Pathways Show Promise in Schizophrenia
Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.
Study: Empagliflozin Reduces MACE Regardless of Baseline Albuminuria Levels
The results further confirm earlier findings from the EMPA-KIDNEY trial.
Challenges and Opportunities for Pharmacists in Clinical Research
Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.
Managing Adverse Event Profiles for Three Bispecific Antibodies Approved for Lymphoma
These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.